Precision Peptide locks exclusive manufacturing for BPC-157, TA1 patches
The company says 20,000 thymosin alpha-1 patches are on order for January 2027 delivery, with tirzepatide and GLP3 patches still in development.
TR
By Tom Reyes · Markets Editor
Oct 22 07:02 ETSource: The Globe and Mail
The wire
- 01The Precision Peptide Company (CSE: BPC) says it secured exclusive rights from its U.S. manufacturer for four transdermal patch formulations: BPC-157, thymosin alpha-1, tirzepatide and GLP3.
- 02Its BPC-157 recovery patch is on sale through a direct-to-consumer and telehealth channel in all 50 states, plus wholesale to clinics, medical spas, gyms and retailers.
- 03The announcement is a company statement about supply and distribution; no clinical data on the patches is presented, and the tirzepatide and GLP3 versions remain in development.
From the source
Read at theglobeandmail.comThe Precision Peptide Company Locks In Exclusive Manufacturing Rights Across Its Needle-Free Line
Four U.S.-made transdermal peptide patches, one manufacturer, one brand: BPC-157 on sale, 20,000 TA1 units in production, Tirzepatide and GLP3 in development
